Author:
Glaviano Antonino,Wander Seth A.,Baird Richard D.,Yap Kenneth C.-H.,Lam Hiu Yan,Toi Masakazu,Carbone Daniela,Geoerger Birgit,Serra Violeta,Jones Robert H.,Ngeow Joanne,Toska Eneda,Stebbing Justin,Crasta Karen,Finn Richard S.,Diana Patrizia,Vuina Karla,de Bruin Robertus A.M.,Surana Uttam,Bardia Aditya,Kumar Alan Prem
Funder
Ministry of Education - Singapore
National University of Singapore
Reference267 articles.
1. Cell cycle control in cancer;Matthews;Nat. Rev. Mol. Cell Biol.,2022
2. The dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative metastatic breast cancer;Grinshpun;NPJ Breast Cancer,2023
3. Mechanisms of resistance to CDK4/6 inhibitors and predictive biomarkers of response in HR+/HER2-metastatic breast cancer-a review of the literature;Stanciu;Diagn. (Basel),2023
4. Immune effects of CDK4/6 inhibitors in patients with HR;Scirocchi;EBioMedicine,2022
5. Novel endocrine therapies: what is next in estrogen receptor positive, HER2 negative breast cancer?;Corti;Cancer Treat. Rev.,2023
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献